Mild Cognitive Impairment in Clinical Practice: A Review Article

  title={Mild Cognitive Impairment in Clinical Practice: A Review Article},
  author={Sukanya Jongsiriyanyong and Panita Limpawattana},
  journal={American Journal of Alzheimer's Disease \& Other Dementias},
  pages={500 - 507}
The spectrum of cognitive decline in the elderly ranges from what can be classified as normal cognitive decline with aging to subjective cognitive impairment to mild cognitive impairment (MCI) to dementia. This article reviewed the up-to-date evidence of MCI including the diagnostic criteria of MCI due to Alzheimer’s disease, vascular cognitive impairment and MCI due to Parkinson disease, management and preventive intervention of MCI. There are various etiologies of MCI, and a large number of… 

Tables from this paper

Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®)

This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia.

New therapeutic approaches to mild cognitive impairment and mild dementia: the role of Ginkgo

There is little evidence to support the efficacy of EGb761® combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EG b761®, in mixed therapy.

Performance of the Rowland Universal Dementia Assessment Scale in Screening Mild Cognitive Impairment at an Outpatient Setting

The RUDAS-Thai performed well in differentiating patients with MCI from normal cognition; however, it was affected by educational level, which affected the test performance according to regression analysis.

Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment

The relationship between the regional distribution of beta-amyloid deposition and grey matter volumetric decreases is associated with deficits in executive function and memory in mild cognitive impairment in people with mild Cognitive impairment and cognitively normal elderly individuals.

The Efficacy of Cocoa Polyphenols in the Treatment of Mild Cognitive Impairment: A Retrospective Study

Dairy supplementation of cocoa flavonoids seems to reduce the progression of MCI to dementia, and further prospective studies with larger sample volumes are required to confirm these promising findings.

Exercise Training-Related Changes in Cortical Gray Matter Diffusivity and Cognitive Function in Mild Cognitive Impairment and Healthy Older Adults

Findings suggest that exercise training may be related to improvements in neural circuits that govern verbal fluency performance in older adults through the microstructural remodeling of cortical gray matter.

Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms.

Enhanced associations between tauopathy and cognitive impairment are present in MCI subjects with behavior symptoms, which is more prominent in the presence of elevated amyloid pathology.

Effect of hearing loss on cognitive function in patients with mild cognitive impairment: A prospective, randomized, and controlled study

HL was significantly negatively associated with cognitive function only in patients with MCI with hearing impairment (HI), and the PTA of the right ear may be a predictor of cognitive decline after 1 year in patients of mild cognitive impairment (MCI with HI).

Prevalence of mild cognitive impairment in surgical menopause: subtypes and associated factors

A high prevalence of MCI and the non-amnestic subtype in women with surgical menopause is found and further study is needed to clarify the long-term effects of surgicalMenopause on cognitive function.



The diagnosis and management of mild cognitive impairment: a clinical review.

Cognitive decline and MCI have important implications for patients and their families and will require that primary care clinicians be skilled in identifying and managing this common disorder as the number of older adults increases in coming decades.

Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia

A systematic review of clinical trials to assess the most current evidence about the efficacy and safety of pharmacologic interventions for preventing or delaying cognitive decline, MCI, and dementia and whether effects differ by patient characteristics.

From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution

Several clinical and biomarker features were proposed to predict risk of conversion to AD in subjects with SCD and further longitudinal studies are needed to support the validity of these high-risk features.

Cognitive Impairment and Dementia in Parkinson’s Disease: Clinical Features, Diagnosis, and Management

This manuscript has synthesized relevant data in order to obtain a pragmatic and updated review regarding cognitive decline in PD, from milder stages to dementia.

Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment.

Even in very mildly impaired individuals who do not meet strict MCI criteria as implemented in clinical trials, the degree of cognitive impairment in daily life and performance on neuropsychological testing predict likelihood of an AD diagnosis within 5 years.

Does Cognitive Training Prevent Cognitive Decline?

This review systematically evaluates the existing literature on the effectiveness of cognitive training in preventing cognitive decline and ADRD as part of a larger systematic review commissioned by the National Institute on Aging to address a range of potential interventions to slow Cognitive decline and prevent or delay dementia.

Mild Cognitive Impairment: A Neuropsychological Perspective

A comprehensive test battery includes measures of baseline intellectual ability, attention, executive function, memory, language, visuospatial skills, and mood and can identify subtle deficits that may otherwise elude detection.

Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts.

Findings add to the growing literature to suggest that the degree of functional impairment at baseline is an important predictor of conversion to dementia and may help explain differences in findings between epidemiological and clinic-based studies.

Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)

The prevalence of MCI recorded in the PACOS sample was approximately 40 and 32% amongst newly diagnosed patients, and a positive significant association between MCI, age and motor scores was found at multivariate logistic regression analysis, while a negative association was observed between educational level and MCI.

Vascular cognitive impairment.

The current nomenclature for vascular cognitive impairment (VCI) is described from the histopathological and clinical perspectives to raise awareness among practitioners about the interaction between conventional and novel vascular risk factors and VCI, with an emphasis on the prevention and risk factor modification.